reports
Agios to Present at the BofA Securities 2024 Health Care Conference on...
Agios to Present at the BofA Securities 2024 Health Care Conference on May 16, 2024 CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the BofA Securities 2024 Health Care Conference on Thursday, May 16, 2024, at 11:40 a.m. ET. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at . A replay of the webcast will be arc...
The Simply Good Foods Company to Participate in the Goldman Sachs Glob...
The Simply Good Foods Company to Participate in the Goldman Sachs Global Staples Forum DENVER, May 06, 2024 (GLOBE NEWSWIRE) -- The Simply Good Foods Company (NASDAQ:SMPL) (“Simply Good Foods” or the “Company”), a developer, marketer and seller of branded nutritional foods and snacking products, today announced that members of the executive management team will participate in a fireside chat at the Goldman Sachs Global Staples Forum on Tuesday, May 14, 2024 at 8:55 a.m. ET. The live audio webcast will be available at within the Events and Presentations section of the Company’s website. ...
OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2...
OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024 MIAMI, May 03, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2024 after the close of the U.S. financial markets on Tuesday, May 7, 2024. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on May 7th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-register f...
Agios to Present at the RBC Capital Markets Global Healthcare Conferen...
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024 CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the 2024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 8:00 a.m. ET. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at . A replay of the webcas...
Agios Reports Business Highlights and First Quarter 2024 Financial Res...
Agios Reports Business Highlights and First Quarter 2024 Financial Results – Topline Data Readout from the Phase 3 ENERGIZE-T Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia now expected in Q2 2024 – – Announced Positive Results from the Phase 3 ENERGIZE Study of Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia in January – – Phase 3 Readouts from Mitapivat RISE UP Study in Sickle Cell Disease, ACTIVATE-KIDS and ACTIVATE KIDS-T in Pediatric PK Deficiency, All Expected by End of 2025 – – PYRUKYND® (Mitapivat) Net Revenue of $...
The Simply Good Foods Company to Acquire Only What You Need (OWYN)
The Simply Good Foods Company to Acquire Only What You Need (OWYN) Adds a fast-growing, on trend, ready-to-drink protein shake brand to Simply Good Foods’ portfolioA scalable, growth-oriented complementary brand with a large and growing addressable marketOWYN is the leading plant-based, allergen-free RTD protein shake in the marketplaceManagement will host a conference call and webcast today at 5:00 p.m. ET DENVER and NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- The Simply Good Foods Company (Nasdaq: SMPL) (“Simply Good Foods,” or the “Company”), a developer, marketer and seller ...
Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delaye...
Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report CHASKA, Minn., April 19, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the “Company”) announced today that, on April 15, 2024, the Company received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the fiscal quarter ended February 25, 2024 (the “Q3 Form 10-Q”) and its continued delay in filing its Quarterly Rep...
Agios to Webcast Conference Call of First Quarter 2024 Financial Resul...
Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024 CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, May 2, 2024, at 8:00 a.m. ET to report its first quarter 2024 financial results and other business highlights. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company'...
Agios Publishes 2024 Environmental, Social and Governance (ESG) Report
Agios Publishes 2024 Environmental, Social and Governance (ESG) Report – Report Highlights Company’s Focus on Red Blood Cell Health; Diversity, Equity & Inclusion; and Strong Corporate Governance – – Aligns with the Sustainability Accounting Standards Board (SASB) Standards for the Biotechnology and Pharmaceuticals Industry and the United Nations Sustainable Development Goals (UN SDGs) – CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced...
The Simply Good Foods Company Reports Fiscal Second Quarter 2024 Finan...
The Simply Good Foods Company Reports Fiscal Second Quarter 2024 Financial Results and Updates Full Fiscal Year 2024 Net Sales and Adjusted EBITDA Outlook DENVER, April 04, 2024 (GLOBE NEWSWIRE) -- The Simply Good Foods Company (Nasdaq: SMPL) (“Simply Good Foods,” or the “Company”), a developer, marketer and seller of branded nutritional foods and snacking products, today reported financial results for the thirteen weeks ended February 24, 2024. Second Quarter Summary:(1) Net sales of $312.2 million versus $296.6 millionNet income of $33.1 million...
Lifecore Biomedical Provides Business Update Outlining Fiscal 2024 Out...
Lifecore Biomedical Provides Business Update Outlining Fiscal 2024 Outlook and Year-to-date Progress Year-to-date Results Consistent with Prior Expectations; Experiencing Fiscal Second Half Lift Provides Fiscal 2024 Full Year Guidance Commercial Momentum Continues within Development Portfolio Capacity Expansion Projects Progressing CHASKA, Minn., April 01, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today provided a business update, including certain se...
Lifecore Biomedical Announces Pending Change of Auditor and Provides E...
Lifecore Biomedical Announces Pending Change of Auditor and Provides Expectation for Business Update CHASKA, Minn., March 26, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), announced today that Ernst & Young LLP, the Company’s independent registered public accounting firm for the fiscal year ended May 28, 2023, determined that it declined to stand for reappointment as the Company’s independent registered public accounting firm for the Company’s fiscal year en...
Moody's changes Matador's outlook to positive, rates proposed unsecure...
Moody's Ratings ("Moody's") assigned a B1 rating to Matador Resources Company's (Matador) proposed senior unsecured notes due 2032. Moody's concurrently changed the company's rating outlook to positive from stable, and affirmed its Ba3 Corporate Family Rating (CFR), Ba3-PD Probability of Default Rat...
- Jonathan Moreland
TTSH TILE SHOP HOLDINGS INC.
OPK OPKO HEALTH INC.
NYCB NEW YORK COMMUNITY BANCORP INC.
MHLD MAIDEN HOLDINGS LTD.
GOGO GOGO INC.
DLTR DOLLAR TREE INC.
CTRN CITI TRENDS INC.
CRMT AMERICA'S CAR-MART INC.
HRTG HERITAGE INSURANCE HOLDINGS INC.
AAOI APPLIED OPTOELECTRONICS INC.
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
VICI VICI PROPERTIES INC
CDLX CARDLYTICS INC
TALO TALOS ENERGY INC.
STKS THE ONE GROUP HOSPITALITY INC.
PAYS PAYSIGN INC
REEMF RARE ELEMENT RESOURCES
DCTH DELCATH SYSTEMS
RZLT REZOLUTE
MYO INC.
XERS MYOMO
LEE XERIS BIOPHARMA HLDGS INC
QSI LEE ENTERPRISES INC
ASLE QUANTUM-SI INC
VPV AERSALE CORP
BPRN INVESCO PA VALUE MUNI INC TST
CYT BANK OF PRINCETON
CYTEIR THERAPEUTICS INC
Lifecore Biomedical Concludes Strategic Evaluation Process, Announces ...
Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Board Changes Appoints Paul Josephs, an executive with 25 years of CDMO experience as CEO, to succeed current CEO James Hall following his retirement Announces changes to its Board of Directors, appoints new Board Chair CHASKA, Minn., March 20, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that its Board of Directors unanimously approved the concl...
Lifecore Biomedical Completes Restatements and Files Form 10-K for Fis...
Lifecore Biomedical Completes Restatements and Files Form 10-K for Fiscal Year 2023 Efforts now aligned toward the completion of its First Quarter Fiscal 2024 Report on Form 10-Q CHASKA, Minn., March 20, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), announced today that it has filed its Annual Report on Form 10-K for the fiscal year ended May 28, 2023 (“FY23”) with the United States Securities and Exchange Commission (the “SEC”). Form 10-K Filing and Resta...
Opko Health Inc: 1 director
A director at Opko Health Inc bought 500,000 shares at 0.874USD and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.